Scarica l'app Stockscreener
5.08
3.79%
-0.20
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NXTC Giù?
Forum
Previsione
Nextcure Inc Borsa (NXTC) Ultime notizie
NextCure Faces Court Review of Reverse Stock Split - TipRanks
About 90% of votes cast backed a share split. NextCure (NXTC) now asks a court to validate it. - Stock Titan
NextCure seeks Delaware court validation of 2025 1-for-12 reverse split ahead of Avere merger - TradingView
Nextcure Stock Price Forecast. Should You Buy NXTC? - StockInvest.us
NextCure, Inc. (NXTC) Discusses Preliminary Phase I Data for SIM0505 in Platinum-Resistant Ovarian Cancer and Uterine Serous CarcinomaSlideshow (NASDAQ:NXTC) 2026-06-02 - Seeking Alpha
NextCure Inc (NASDAQ: NXTC) Stock Price, News & Analysis - Kalkine
NXTC|NextCure Inc|Price:7.860|Chg%:+0.040 - TradingKey
NextCure Ends Beltsville Lease to Cut Operating Costs - TipRanks
About 30,000 sq ft of lab as NextCure (NXTC) exits Maryland site—what it paid to leave early - Stock Titan
NextCure Enters Into Ninth Amendment To Lease Agreement And Vacates Premises At 8000 Virginia Manor Road - marketscreener.com
ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds NextCure, Inc. Investors of Important November 20 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact FirmNXTC - TMX Newsfile
NextCure - thepharmaletter.com
NextCure (NXTC) Q2 2026 Earnings: Profit Per Share Falls Below Its Benchmark for the Current Session - vinanet.vn
NextCure (NASDAQ: NXTC) plans Avere merger backed by $820M raise - Stock Titan
NextCure (NXTC) Share-Price Review: Declines 11.15% to $6.85 at the Close; Current Range Read: the Near-Term Reference Band Stretches From $6.51 to $7.19 under the Current SnapshotExtension Target - vinanet.vn
Ikarian Capital discloses 9.99% NextCure (NXTC) stake including large warrant position - Stock Titan
NextCure (NXTC) gains 15.8% beneficial owner in ADAR1 Capital and manager - Stock Titan
NextCure (NXTC): Squadron funds and partners disclose 1.6% equity stake - Stock Titan
Affinity Asset Advisors discloses 6.4% NextCure (NXTC) stake via stock and warrants - Stock Titan
NextCure stock rating reiterated at Buy by H.C. Wainwright - Investing.com
Major Former Stakeholder Makes a Significant Move in NextCure Stock - TipRanks
Simcere Zaiming sells $184,800 of NextCure stock By Investing.com - Investing.com India
Adage Capital files Schedule 13G showing 7.67% NextCure (NXTC) ownership - Stock Titan
Simcere Zaiming sells $184,800 of NextCure stock - Investing.com
Simcere group (NXTC) trims NextCure stake, ends 10% beneficial ownership - Stock Titan
RTW Biotech's Avere to go public in US in reverse merger with NextCure - London South East
NXTC Q2 2026 Earnings: 42% EPS Miss Yet Shares Rally 21.4%Earnings Turnaround - dars.gov.et
RTW Biotech Opportunities (RTWG) Supports Avere Therapeutics’ $820M Capital Raise and NextCure Reverse Merger - Kalkine Media
NextCure (NXTC) plans reverse merger with Avere and $820M financings - Stock Titan
Xcellon Acquires 40,000 Sq ft Maryland Facility from NextCure to Deliver a cGMP-Ready CRDMO for ADCs - BioBuzz
Xcellon Biologics Acquires GMP Manufacturing Facility from NextCure, Becoming an End-to-End CRDMO for Next-Generation Bioconjugates and Complex Biologics - The Manila Times
Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001 - Nasdaq
NextCure Inc (NXTC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NextCure Provides Business Update and Reports Second Quarter 2026 Financial Results - The Manila Times
NextCure reports Q2 2026 net loss $14.9M, cash $20.1M as it pursues merger with Avere - TradingView
NextCure, Inc. Q2 2026: Net income $(14.9)M, EPS $(2.80) — 10-Q Summary - TradingView
NextCure (NASDAQ: NXTC) details Avere merger, $320M financing and going concern risk - Stock Titan
NextCure (Nasdaq: NXTC) details Q2 2026 loss and Avere merger - Stock Titan
NextCure (NXTC) details two-step Avere merger plan and upcoming Form S-4 - Stock Titan
Form 4 NextCure Inc For: 4 August By Investing.com - Investing.com UK
Adar1 Capital Management buys $1.6m in NextCure (NXTC) shares - Investing.com
Adar1 Capital Management buys $1.6m in NextCure (NXTC) shares By Investing.com - Investing.com India
ADAR1 Capital Management reports NextCure common share purchase worth $3.59 million - Bitget
ADAR1-managed funds buy 329,153 shares of NextCure (NXTC) - Stock Titan
Avere Therapeutics - The Pharma Letter
NextCure Inc expected to post a loss of $1.93 a shareEarnings Preview - TradingView
NextCure Stock Short Interest Rises to 32.54% | NXTC Stock News - Quiver Quantitative
NextCure, Inc. Revenue Breakdown – NASDAQ:NXTC - TradingView
NextCure (NXTC) Holds Steady Near Key Support LevelsStraddle Setup - dars.gov.et
3.06%
2.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):